1-(5-benzofuranyl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(5-benzofuranyl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone
• 英文别名: (5-benzofuranyl)-3-[1-(phenylmethyl)-4-piperidinyl]-1-propanone；1-(1-Benzofuran-5-yl)-3-(1-benzylpiperidin-4-yl)propan-1-one
• 化学式: C₂₃H₂₅NO₂
• 分子量: 347.457
• InChiKey: SGUUCMAJRUJNIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  33.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE<br/>[FR] INTERMÉDIAIRES DE LACTONE DE NICOTINAMIDE RIBOSIDE ET DE NICOTINATE RIBOSIDE
  申请人：UNIV BELFAST

  公开号：WO2018033639A1

  公开（公告）日：2018-02-22

  The present invention is directed to lactones of the following structural formula for use as precursors of NAD, and their use as nutritional supplements.

  本发明涉及以下结构式的内酯，用作NAD的前体，并且它们的用途作为营养补充剂。
• Heteroaryl amines as novel acetylcholinesterase inhibitors
  申请人：——

  公开号：US20020049210A1

  公开（公告）日：2002-04-25

  Compounds of the formula 1 wherein ring A, ring B, ring D, R 2 , R 3 , R 4 , R 5 , R 6 ,R 11 , R 12 , R 13 , E, G, X and P are as defined below. The compounds of formula I are cholinesterase inhibitors and are useful in enhancing memory in patients suffering from dementia and Alzheimer's disease.

  化合物的公式为1，其中环A、环B、环D、R2、R3、R4、R5、R6、R11、R12、R13、E、G、X和P的定义如下。式I的化合物是胆碱酯酶抑制剂，对于患有痴呆症和阿尔茨海默病的患者增强记忆力具有有用的作用。
• Modulators of CDC2-like kinases (CLKS) and methods of use thereof
  申请人：Milne Jill

  公开号：US20070248590A1

  公开（公告）日：2007-10-25

  Provided herein are methods for using Cdc2-like kinase (Clk) modulators for treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, ocular disorders, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a Clk modulating compound in combination with another therapeutic agent.

  本文提供了使用Cdc2-like kinase (Clk)调节剂治疗和/或预防各种疾病和障碍的方法，包括与衰老或压力有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝结障碍、炎症、癌症、眼部疾病和/或潮红，以及需要增加线粒体活动的疾病或障碍。此外，提供了包含Clk调节化合物与另一种治疗剂联合使用的组合物。
• Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
  申请人：Milburn Michael

  公开号：US20060276393A1

  公开（公告）日：2006-12-07

  Provided herein are methods and compositions for treating or preventing neurodegenerative disorders or blood coagulation disorders. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin; or an inhibitory compound, such as nicotinamide.

  本文提供了治疗或预防神经退行性疾病或血液凝固疾病的方法和组合物。方法可以包括调节sirtuin的活性或水平，例如SIRT1或Sir2。示例方法包括使用sirtuin激活化合物（例如黄酮，苯乙烯，黄烷酮，异黄酮，儿茶素，查尔酮，单宁或花青素）或抑制化合物（例如烟酰胺）与细胞接触。
• Acridine and Quinoline Derivatives as Sirtuin Modulators
  申请人：Milburn Michael

  公开号：US20090069301A1

  公开（公告）日：2009-03-12

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, chemotherapeutic induced neuropathy, neuropathy associated with an ischemic event, polyglutamine diseases, ocular diseases and/or disorders, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新颖的sirtuin调节化合物及其使用方法。这些sirtuin调节化合物可用于增加细胞寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或压力有关的疾病或疾病，糖尿病，肥胖症，神经退行性疾病，化疗引起的神经病理性疼痛，缺血事件相关的神经病理性疼痛，多谷氨酸疾病，眼部疾病和/或疾病，心血管疾病，血栓形成障碍，炎症，癌症和/或潮红。还提供了包含sirtuin调节化合物与另一种治疗剂组合的组合物。